Literature DB >> 14614304

Evaluation of expression patterns of feline CD28 and CTLA-4 in feline immunodeficiency virus (FIV)-infected and FIV antigen-induced PBMC.

I S Choi1, H S Yoo, E W Collisson.   

Abstract

It is known that CD28, a positive costimulatory receptor, plays a very important role in inducing the optimal stimulation of T lymphocytes. CTLA-4 (CD152), however, acts as a negative regulator in T lymphocyte activation. The effect of an feline immunodeficiency virus (FIV) infection on the expression of feline CD28 and CTLA-4 was studied with FIV-infected and uninfected peripheral blood mononuclear cells (PBMC) using a competitive PCR assay. The nature of CD28 and CTLA-4 expression was also examined with fresh and antigen-stimulated PBMC. FIV infection induced a lower expression of CD28, but a higher expression of CTLA-4 in the infected PBMC than in the uninfected PBMC. Relatively high levels of CD28 expression were demonstrated in both the fresh and the antigen-stimulated PBMC. The expression level of CTLA-4 in the freshly isolated PBMC was rather low, however, FIV antigen stimulation induced a relatively high expression of CTLA-4 in feline PBMC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 14614304

Source DB:  PubMed          Journal:  J Vet Sci        ISSN: 1229-845X            Impact factor:   1.672


  3 in total

Review 1.  Clinical aspects of feline immunodeficiency and feline leukemia virus infection.

Authors:  Katrin Hartmann
Journal:  Vet Immunol Immunopathol       Date:  2011-07-21       Impact factor: 2.046

Review 2.  Clinical aspects of feline retroviruses: a review.

Authors:  Katrin Hartmann
Journal:  Viruses       Date:  2012-10-31       Impact factor: 5.048

3.  Association between CTLA-4 gene polymorphism and risk of rheumatoid arthritis: a meta-analysis.

Authors:  Chuankun Zhou; Shutao Gao; Xi Yuan; Zixing Shu; Song Li; Xuying Sun; Jun Xiao; Hui Liu
Journal:  Aging (Albany NY)       Date:  2021-08-02       Impact factor: 5.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.